focus -WSS

focus

author：comprehensive 2025-09-30 17:29:25 - browse：88

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Melinda French Gates resigns from Gates Foundation

hotspot

WSS

CDC recommends RSV monoclonal antibody for infants

Cancer researcher Catriona Jamieson is sending tumors into space

H.R. 3 is the wrong path to lower drug costs

After traumatic brain injury, life support decisions can use more time

Element Biosciences CEO lays out genome sequencing strategy

Diversity in clinical trials starts with building trust, experts say

explore

focus

hotspot

Supreme Court strikes down use of affirmative action

Dogs on Prozac: What pet anti

Wildfire smoke exposes gaps in outdoor worker protections

Health care needs a new profession: neuroimaging counseling

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Exact Sciences stock tumbles despite strong cancer detection sales

Malaria cases in Florida and Texas: Here’s what you need to know

The cancer stories no one wants to hear

Drug repurposing or repositioning? The language matters

Cancer researcher Catriona Jamieson is sending tumors into space

entertainment

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

FDA approves Sage Therapeutics’ rapid

Cell therapy fails to slow type 1 diabetes, but safety is established

FDA scientists endorse Pfizer/BioNTech Covid

FDA scientists endorse Pfizer/BioNTech Covid

Flint parents haunted by uncertainty, fears of lead poisoning

hotspot

explore

hotspot

focus